Kentucky Retirement Systems Insurance Trust Fund Has $604,000 Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Kentucky Retirement Systems Insurance Trust Fund lowered its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 11.2% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,746 shares of the medical equipment provider’s stock after selling 980 shares during the quarter. Kentucky Retirement Systems Insurance Trust Fund’s holdings in Hologic were worth $604,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Raymond James & Associates grew its position in Hologic by 9.9% during the fourth quarter. Raymond James & Associates now owns 276,880 shares of the medical equipment provider’s stock worth $19,783,000 after buying an additional 24,867 shares in the last quarter. McGlone Suttner Wealth Management Inc. bought a new position in shares of Hologic in the fourth quarter worth $27,000. Blue Trust Inc. increased its position in shares of Hologic by 28.7% in the fourth quarter. Blue Trust Inc. now owns 3,538 shares of the medical equipment provider’s stock worth $245,000 after purchasing an additional 790 shares during the period. Fifth Third Bancorp raised its stake in Hologic by 9.3% in the fourth quarter. Fifth Third Bancorp now owns 41,331 shares of the medical equipment provider’s stock valued at $2,953,000 after purchasing an additional 3,518 shares in the last quarter. Finally, Allen Mooney & Barnes Investment Advisors LLC lifted its position in Hologic by 3.1% during the fourth quarter. Allen Mooney & Barnes Investment Advisors LLC now owns 12,818 shares of the medical equipment provider’s stock worth $916,000 after purchasing an additional 390 shares during the period. Institutional investors own 94.73% of the company’s stock.

Insider Activity at Hologic

In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the transaction, the director now directly owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the transaction, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now directly owns 45,472 shares in the company, valued at approximately $3,615,024. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by company insiders.

Hologic Trading Up 1.0 %

Shares of NASDAQ:HOLX traded up $0.75 during midday trading on Friday, hitting $78.63. 1,472,174 shares of the stock were exchanged, compared to its average volume of 1,435,837. The business’s 50-day moving average price is $74.56 and its 200 day moving average price is $75.03. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $82.31. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.29 and a current ratio of 3.97. The stock has a market capitalization of $18.35 billion, a price-to-earnings ratio of 40.12, a P/E/G ratio of 2.62 and a beta of 0.99.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The company’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.06 EPS. Analysts predict that Hologic, Inc. will post 4.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on HOLX. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Needham & Company LLC restated a “buy” rating and set a $90.00 price objective on shares of Hologic in a research report on Friday, May 3rd. Argus raised their target price on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, May 9th. Stephens started coverage on Hologic in a report on Thursday, June 27th. They set an “overweight” rating and a $87.00 price target for the company. Finally, Evercore ISI reduced their price objective on Hologic from $78.00 to $76.00 and set an “in-line” rating on the stock in a research note on Tuesday, July 2nd. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $85.55.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.